About this trial
The purpose of this study is to test the efficacy of SUFICS-PACT to identify and treat sexual and urinary dysfunction in prostate cancer survivors at NYC H+ H/Bellevue, the oldest public hospital in the US. This study will evaluate the implementation of an adapted sexual and urinary function collaborative care model at NYC Health+Hospitals/Bellevue. The study will test the efficacy of this collaborative care model through a randomized controlled trial in the adult primary care clinic; the intervention arm will receive collaborative treatment consisting of a care manager who has specialty training in mental health and psychosexual counseling, a primary care nurse practitioner who leads symptom management, primary care physicians who supervise the team, and a team specialty consult liaison.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
At least 18 years old
Have a diagnosis of prostate cancer
Have sought care/treatment for prostate cancer
Disqualifiers
Patients under 18 years old
Patients who have not sought care/treatment for prostate cancer
Patients who are categorized as "vulnerable subjects," such as minors or incarcerated individuals.
Trial design
Parallel
Treatments tested in this trial
SUFICS-PACT
BehavioralSUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
Treatment groups
Trial outcomes
Primary outcomes
Number of patients identified and treated for sexual dysfunction
Number of patients identified and treated for urinary dysfunction
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: